Participant flow

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy · Source last updated 2020-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day)

   id

   FG000

   title

   Non-Biopsied Diffuse Instrinsic Pontine Glioma/Diffuse Midline Glioma

periods

1. milestones

   1. achievements

      1. comment

         11 participants were enrolled however 1 participant withdrew before starting study treatment.

         group Id

         FG000

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice